Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix (NASDAQ: BDSX), a leading diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will participate in the fireside chat at Cowen’s 43rd Annual Healthcare Conference from March 6-8, 2023. The chat is scheduled for March 7 at 1:30 PM ET at Boston Marriott Copley Place. It will also be webcast live on the company's website. Biodesix leverages AI to develop diagnostic tests for lung diseases, offering five Medicare-covered tests, including Nodify Lung and IQLung strategies, which aid in assessment and treatment of lung diseases. For more details, visit biodesix.com.
Biodesix, Inc. (BDSX) announced it will release its financial results for Q4 and the fiscal year ending December 31, 2022, before the market opens on March 6. A conference call and webcast will follow at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Biodesix specializes in data-driven diagnostic solutions for lung diseases, utilizing AI for diagnostic tests. Their services include five Medicare-covered tests, notably for lung cancer patients aiming to expedite treatment. Biodesix's strategic partnerships with biotech firms enhance diagnostic capabilities in lung care.
Biodesix, Inc. (BDSX) announced positive coverage decisions for its Nodify XL2® test from four private payers, including Blue Cross Blue Shield of North Carolina and South Carolina, effective Q4 2022. This expands coverage to approximately 4.5 million lives, enhancing access to its diagnostic solutions for lung disease. The Nodify XL2 test boasts a 98% negative predictive value, aiding healthcare professionals in avoiding unnecessary procedures. This milestone reflects the growing recognition of Biodesix's diagnostic value within the lung cancer continuum of care.
Biodesix, Inc. (NASDAQ: BDSX) has appointed Lawrence (Lair) T. Kennedy, Jr. to its Board of Directors and Audit Committee effective January 3, 2023. Kennedy brings over 20 years of experience in corporate finance and healthcare. His extensive background includes leadership roles in healthcare staffing and investment management. CEO Scott Hutton expressed optimism that Kennedy's expertise will enhance the Board's effectiveness as the company aims to improve lung cancer diagnostics and treatment through data-driven solutions, including five Medicare-covered tests.
Biodesix, Inc. (NASDAQ: BDSX) has been recognized as the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine in its December 2022 issue. With over 15 years in clinical proteomics, Biodesix specializes in identifying patients' immune responses to cancer using blood-based tests. The company has performed over 125,000 proteomic tests and currently offers three clinical tests, enabling faster and more accurate diagnosis and treatment strategies for lung cancer. This recognition underscores Biodesix's commitment to advancing diagnostic solutions in lung disease.
Biodesix, Inc. (NASDAQ: BDSX) has announced the pricing of a public offering of 30,500,000 shares at $1.15 each, aiming to raise approximately
Biodesix, Inc. (NASDAQ: BDSX) has initiated an underwritten public offering of $30 million in common stock. The company may offer an additional $4.5 million of shares if underwriters exercise their option. The proceeds will fund commercial expansion, support R&D, and cover general corporate expenses. The offering is subject to market conditions and other factors. William Blair is the sole bookrunning manager. The shares will be sold under a shelf registration statement filed with the SEC in November 2021.
Biodesix (BDSX) has secured a
Biodesix announces new interim data from the INSIGHT study, presented by Dr. Wallace Akerley at the SITC 37th Annual Meeting on November 11, 2022. The study confirms the VeriStrat test's ability to predict outcomes in patients with Non-small Cell Lung Cancer (NSCLC) treated with immunotherapy. Analysis of 3,040 patients shows that HIC-C classification results in better median overall survival when combined with chemotherapy. The data underscores the importance of biomarker-driven strategies for optimal treatment.
Biodesix reported a 102% increase in core lung diagnostic revenue to $9.2 million for Q3 2022 compared to Q3 2021. Total revenue reached $11.1 million, up 70% year-over-year, driven by strong adoption of Nodify tests. Medicare now covers all five core lung diagnostic tests, enhancing growth prospects. Despite a net loss of $13.7 million, a decrease in operating loss indicates improved financial health. Cash reserves stand at $15.2 million. The company expects to meet its revenue guidance of $37.5-$39.5 million for 2022, emphasizing growth in lung diagnostics.